XPH(SZ:300147) Xin Lang Cai Jing·2025-10-24 13:01Core Viewpoint - The company is preparing to enter the confirmatory clinical trial phase for its drug TAEST16001, which has already received approval from the CDE and has undergone expert discussions, indicating readiness for patient enrollment [1] Group 1: Clinical Trial Progress - The company has confirmed that TAEST16001 is set to enter the confirmatory clinical trial phase [1] - The chairman previously mentioned the goal of entering this phase soon, highlighting the urgency of the timeline [1] - The company is aware of the importance of enrollment progress for pipeline advancement, especially in light of ADAP's recent delisting due to insufficient R&D efficiency [1] Group 2: Information Disclosure - The company will disclose the progress of new drug development according to information disclosure rules and actual circumstances through official announcements [1] - Investors are encouraged to pay attention to the company's announcements for updates on enrollment timelines and current progress [1]